

Ministry of Health

Office of Chief Medical Officer
of Health, Public Health

Box 12,
Toronto, ON M7A 1N3

Fax: 416 325-8412

Ministère de la Santé

Bureau du médecin hygiéniste
en chef, santé publique

Boîte à lettres 12
Toronto, ON M7A 1N3

Télec. :416 325-8412

July 2, 2024

Dear Health Care Provider,

This letter is to inform you that Ontario's publicly funded pneumococcal vaccine program is transitioning to the following new pneumococcal vaccines:

- Pneumococcal 15-valent conjugate (Pneu-C-15), Vaxneuvance
- Pneumococcal 20-valent conjugate (Pneu-C-20), Prevnar 20

These two new pneumococcal conjugate vaccines will provide broader protection against invasive pneumococcal disease (IPD) compared to Pneu-C-13 and longer-term protection than Pneu-P-23, which are currently used in the provincial program.

The Pneu-C-15 vaccine is for use in the routine pediatric pneumococcal vaccine program and the Pneu-C-20 is for use in the high-risk programs and the routine adult program 65+. Please note eligibility for these programs is not changing and re-vaccination is not part of the product transition. Any future changes in eligibility will be communicated separately.

Please refer to the following attachments for additional information:

- Health Care Provider Fact Sheet: Pneumococcal Conjugate Vaccines for Children Aged 6 Weeks to 4 Years
- Health Care Provider Fact Sheet: Pneumococcal Conjugate Vaccine for High-Risk Individuals Aged 5 to 64 Years
- Health Care Provider Fact Sheet: Pneumococcal Conjugate Vaccine for Individuals Aged 65 Years and Older
- Vaccine Fact Sheet: Pneumococcal Vaccine Program for Individuals Aged 6 Weeks and Older
- Qs & As for Health Care Providers: Pneumococcal Vaccine Transition

The program transition is planned for July 29, 2024. Details on ordering Pneu-C-15 and Pneu-C-20 vaccines will be shared by your local public health unit.

Should you or your staff have any questions, please contact your local public health unit.

We thank you for your continued support and dedication to the publicly funded immunization program, protecting Ontarians against vaccine preventable diseases.

Sincerely,

A handwritten signature in black ink, appearing to read "Kieran Moore". The signature is fluid and cursive, with a large initial "K" and "M".

Dr. Kieran Michael Moore, MD, CCFP(EM), FCFP, MPH, DTM&H, FRCPC, FCAHS
Chief Medical Officer of Health and Assistant Deputy Minister, Public Health

c: Dr. Daniel Warshafsky, Associate Chief Medical Officer of Health
Michael Sherar, President and Chief Executive Office, Public Health Ontario